New York — The Physicians Coalition for Injectable Safety recently announced its support of actions taken by the Kansas State Board of Healing Arts to significantly restrict the use of LipoDissolve, a controversial fat-dissolving injectable.
The Kansas Board says patients must not receive LipoDissolve unless it is authorized by a physician as part of an investigational drug trial. In a prepared statement, the Coalition said the Kansas position “is appropriate and significant in protecting consumer safety and restricting treatment of non-FDA approved, compounded, injectable substances into the human body.”
The Coalition, made up of the American Society for Aesthetic Plastic Surgery, The American Academy of Facial Plastic and Reconstructive Surgeons and the American Society of Ophthalmic Plastic and Reconstructive Surgery, says no formal studies of mesotherapy or LipoDissolve demonstrate efficacy or safety and cautions that reports of complications include skin infection, disfigurement, severe cramping, bloating and dehydration. The Coalition statement says consumers in all 50 states should take note of the Kansas State Board’s actions, which the Coalition calls “the most appropriate in protecting consumer health and safety with an unproven and widely marketed treatment.”
